51. Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features
- Author
-
Sijin Yang, Yanguang Cong, and Xiancai Rao
- Subjects
0301 basic medicine ,Vancomycin-resistant Staphylococcus aureus ,Review Article ,vanA cluster ,medicine.disease_cause ,Microbiology ,03 medical and health sciences ,0302 clinical medicine ,Vancomycin ,medicine ,lcsh:Science (General) ,ComputingMethodologies_COMPUTERGRAPHICS ,lcsh:R5-920 ,Multidisciplinary ,biology ,business.industry ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,biology.organism_classification ,Treatment ,Vana gene ,030104 developmental biology ,Enterococcus ,Staphylococcus aureus ,030220 oncology & carcinogenesis ,lcsh:Medicine (General) ,business ,lcsh:Q1-390 ,medicine.drug - Abstract
Graphical abstract, Highlights • MRSA infection is a global threat to public health. • Vancomycin is one of the first-line drugs for the treatment of MRSA infections. • MRSA with complete resistance to vancomycin have emerged in recent years. • The total number of VRSA isolates is updated in this paper. • Resistance mechanisms, characteristics of VRSA infections, as well as clinical treatments are reviewed., The infection caused by methicillin-resistant Staphylococcus aureus (MRSA) is a global threat to public health. Vancomycin remains one of the first-line drugs for the treatment of MRSA infections. However, S. aureus isolates with complete resistance to vancomycin have emerged in recent years. Vancomycin-resistant S. aureus (VRSA) is mediated by a vanA gene cluster, which is transferred from vancomycin-resistant enterococcus. Since the first VRSA isolate was recovered from Michigan, USA in 2002, 52 VRSA strains have been isolated worldwide. In this paper, we review the latest progresses in VRSA, highlighting its resistance mechanism, characteristics of VRSA infections, as well as clinical treatments.
- Published
- 2020
- Full Text
- View/download PDF